Details
Category: Volume 08 Issue 01 January 2020
Hits: 1082

Title: A Clinical Study of Risk Factors for Extensive Drug Resistance (XDR) Tuberculosis in Tertiary Care Hospital

Authors: Dr T. Jahnavi, Prof. K.V.V. Vijaya Kumar M.D., Dr V.Surya Kumari M.D., Dr B. Padmaja M.D

 DOI: https://dx.doi.org/10.18535/jmscr/v8i1.10

Abstract

XDR-TB involves resistance to the two most powerful anti-TB drugs, isoniazid and rifampicin, also known as multidrug-resistance (MDR-TB), in addition to resistance to any of the fluoro quinolones (such as levofloxacin or moxifloxacin) and to at least one of the three injectable second-line drugs (amikacin, capreomycin or kanamycin).

Aim: To know the various risk factors for XDR tuberculosis and most common types of drug resistant patterns in XDR tuberculosis.

Materials and Methods: This study was a hospital based record based study Conducted at DR-TB CENTRE, Department of pulmonary medicine, Government hospital for chest and communicable diseases (GHCCD), Andhra medical college, Visakhapatnam. It’s a 2 years study conducted from September 2017 to August  2019 .Total number of 18 XDR tuberculosis patients were enrolled in the study based on inclusion and exclusion criteria and all the patients were  subjected to sputum for CBNAAT  and line probe assay(first and second line).

Results: In the present study majority were males (83.3%), majority (38.8%) were younger age group between age 31 to 40 years, most of the drug resistance pattern noticed for kanamycin combined with ofloxacin, 66.6% were MDR-TB failures. Smoking (77.7%), alcohol (72.2%), lower BMI (77.7%) were major risk factors and HIV (33.3%), hypertension (38.8%), diabetes (55.5%) were major Comorbidities in the present study.

Keywords: XDR-TB, MDR-TB, CBNAAT, DR-TB CENTRE, LPA  etc.

References

  1. WHO Global Tuberculosis Report 2019. Geneva: WHO Available from: https://apps.who.int/iris/bitstream/handle/10665/329368/9789241565714-eng.pdf?ua=1
  2. World Health Organization. Tuberculosis: Frequently asked Questions-XDR-TB, 2012. Available from: http://www.who.int/tb/ challenges/xdr/faqs/en/index.html. [Updated on 2012 Jan 26; Cited on 2012 Jun 26].
  3. Sharma SK, George N, Kadhiravan T, Saha PK, Mishra HK, HanifM.Prevalence of extensively drug-resistant tuberculosis among patients with multidrug resistant tuberculosis: A retrospective hospital based study. Indian J Med Res 2009;130:392-5.
  4. Myneedu VP, Visalakshi P, Verma AK, Behera D, Bhalla M. Prevalence of XDR TB cases: A retrospective study from a tertiary care TB hospital. Indian J Tuberc 2011;58:54-9.
  5. Kim HR, Hwang SS, Kim HJ, Lee SM, Yoo CG, Kim YW, et al. Impact of extensive Drug-resistance on treatment outcomes in non/HIV/infectedpatients with multidrug/resistant tuberculosis. Clin Infect Dis2007;45:1290-5.
  6. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB.Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta/analysis. Clin Infect Dis2010;51:614.
  7. Gandhi NR, Moll A, Sturm AW, Pawinski R, Govender T, Lalloo U, et al.Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Lancet 2006;368:1575-80.
  8. Geneva: World Health Organization; 2008. Anti-Tuberculosis Drug Resistance in the World. Report no. 4. [Google Scholar] [Ref list]
  9. Extensively drug-resistant tuberculosis in the United States, 1993-2007.Shah NS, Pratt R, Armstrong L, Robison V, Castro KG, Cegielski JP JAMA. 2008 Nov 12; 300(18):2153-60.[PubMed] [Ref list].
  10. Ignatyeva O, Balabanova Y, Nikolayevskyy V, Koshkarova E, Radiulyte B, Davidaviciene E, et al. Resistance profile and risk factors of drug resistant    tuberculosis in the Baltic countries.Tuberculosis(Edinb) 2015; 95 : 581-8.
  11. Porwal C, Kaushik A, Makkar N, Banavaliker JN, HanifM,Singla R, et al. Incidence and risk factors for extensively drug-resistant tuberculosis in Delhi region. PLoS One 2013; 8 : e55299.
  12. Chih-Cheng Lai, Che-Kim Tan, Yu-Tsung Huang, Chien-Hong Chou, Chien-Ching Hung, Pan-Chyr  Yang,Kwen-Tay Luh, Po-Ren HsuehClinical Infectious   Diseases, Volume 47, Issue 7, 1 October 2008, Pages e57e63, https://doi.org/10.1086/591702 Published:01 October 2008.
  13. Kwon YS, Kim YH, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Treatment outcomes for HIV-uninfected patients with multidrug-resistant and extensively drug-resistant tuberculosis. Clin Infect Dis. 2008;47:496–502.  [PubMed] [Google Scholar].
  14. Medea Gegia,a,*IagorKalandadze,a Russel R. Kempker,b Matthew J. Magee,b and Henry M. BlumbergbInt J Infect Dis. Author manuscript; available in PMC 2013 Sep 28.Published in final edited form as:Int J Infect Dis. 2012 May; 16(5): e391–e396.Published online 2012 Mar 17. doi: 1016/j.ijid.2011.12.018.
  15. Atre SR, Mistry NF. Multidrug-resistant tuberculosis (MDR-TB) in India: an attempt to link biosocial determinants. J Public Health    2005;26:96–  114. [PubMed] [Google Scholar].
  16. Paramasivan CN, Venkataraman P. Drug resistance in tuberculosis inIndia. Indian J Med Res. 2004;120:377–386. [PubMed] [Google Scholar].

Corresponding Author

Dr T. Jahnavi

Post graduate, Department of Pulmonary Medicine Andhra Medical College/ NTR University